Topics
March 2013 | Special Cover Features: Medical Innovation In Retina
Integrin Peptide Therapy for the Treatment of Vascular Eye Diseases
In addition to its effects in DME, this molecule can induce posterior vitreous detachment.
Baruch D. Kuppermann, MD, PhD
October 16, 2026
Alvotech and Advanz Pharma Submit European Application for First Proposed Eylea 8 mg Biosimilar
FDA Approves Genentech's Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
October 15, 2026
Study Finds Rising Demand for Emergency Ophthalmology Consultations Across US Academic Centers
Eclipse Life Sciences Reports Positive Phase 2 Results for EC-104 in DME
October 2026 Insert
Editorially Independent Content, Supported With Advertising From Asetllas
Editorially independent supported by Abbvie and Regenxbio
Free Print Subscription
Email Newsletter
Conference Calendar
